Drs. Ron Waksman and Spencer King discuss a recent editorial that Dr. King wrote for Cardiovascular Revascularization Medicine concerning the many iterations of anticoagulation regimens. Dr. King notes the conflicting signals from different trials examining antithrombotic therapy after PCI in patients presenting with different conditions. One key point is the search for the right balance between bleeding and thrombotic risk, but does this mean lower doses of antithrombotic agents, a shorter duration of antiplatelet therapy, or something else? The struggle is real.
